11% OF AMERICANS ARE ON A GLP-1

I've seen figures of 8% by the end of 2025, 12% by the end of the first quarter, and recently 15%.

I think that, just like 83.25% of the statistics, they're completely made up. /j

That can't be far from the reality, but there must be a lot of marketing propaganda to expand the market.

What's sure is that Lindt has said they're selling more dark chocolate in the U.S., and T-shirt makers have already had to adjust their production mix by size.

TL;DR (Notebooklm)

A recent Gallup survey reveals that GLP-1 usage in the United States has reached a critical turning point, with 11% of Americans currently using these medications for weight management. Data shows that public awareness of these drugs has surged to 91%, while national obesity rates have begun to decline for the first time in years. The report highlights a significant trend where patients using compounded versions of the medication often report higher satisfaction levels regarding effectiveness compared to those on branded versions. Furthermore, upcoming expansions in Medicare and Medicaid coverage are expected to provide millions more with access, potentially stabilizing Type 2 diabetes rates through early intervention. Ultimately, the discussion emphasizes a shift toward personalized obesity medicine that integrates hormonal health and metabolic signaling to improve long-term patient outcomes.

Click to expand...
Click to expand...

10 key ideas (Notebooklm)

Based on the transcript of the Gallup 2024 report overview, here are the 10 key ideas regarding the current state of GLP-1 usage:

  1. Explosive Growth in Usage: Currently, 11% of Americans (approximately 29 million people) are taking GLP-1 medications for weight management, a massive increase from only 3% just two years ago.
  2. A Healthcare Tipping Point: The medications have moved from "early adoption" to mainstream medicine, with 15% of Americans (nearly 40 million people) having tried a GLP-1 at some point.
  3. Historic Decline in Obesity Rates: For the first time in recent history, U.S. obesity rates are falling, dropping from 39.9% in 2022 to 36.4%, a trend directly correlated with the rise of GLP-1 use.
  4. Stabilization of Type 2 Diabetes: After years of steady increases, diabetes rates are beginning to level off. Data suggests that using these medications for weight management serves as a powerful prophylaxis, with one study showing 94% of pre-diabetic patients did not progress to type 2 diabetes.
  5. Higher Satisfaction with Compounded Medications: Surprisingly, patients using compounded GLP-1s rated their experience slightly higher than those on brand-name drugs, with 39% of compounded users reporting the treatment as "extremely effective" compared to 32% for branded users.
  6. Cost is the Primary Driver for Switching: Cost remains the number one factor (66%) leading patients to switch from brand-name medications to compounded versions, particularly when they lose insurance coverage.
  7. Expanding Access Through Medicare and Medicaid: Millions more Americans are gaining access as Medicare expands coverage. Furthermore, by 2027, Medicaid programs will be able to purchase these drugs for $250, which is expected to trigger a massive expansion in access for lower-income populations.
  8. Benefits Beyond Weight and Diabetes: GLP-1s are showing significant potential in treating adjacent conditions, including obstructive sleep apnea, cardiovascular events, and non-alcoholic fatty liver disease.
  9. Universal Public Awareness: Knowledge of these drugs has become nearly universal, rising from 80% in 2024 to 91% in 2026. The public conversation has shifted from "What is Ozempic?" to specific questions about dosage, insurance, and long-term maintenance.
  10. The Importance of the Gut-Brain Axis: Recent research highlights that the nervous system is the "loudest signal" for metabolism. This underscores the need for holistic care that addresses mental health, stress (cortisol), and individualized hormonal signaling rather than just focusing on a single pathway.
 
The government bridge program got millions to start because it's only $50 a month. I doubt the majority will be successful long term because these drugs are not magic. You have to establish a consistent calorie deficit and few know this or are capable of doing this. It's still work to lose weight and most don't care enough to modify what they eat or how much activity is needed.
 
I was at lunch with a group of senior citizens yesterday, exactly half of our group were on GLPs, and only one had made it known before the topic came up and the rest fessed up. With seniors at least I think there comes a point where we have to tell people or they're starting whispering about what godawful disease poor Edna must have, wonder how much longer she's got? 🙄 🤣
 
I bet the reality is even higher. Many people don't really understand their meds, the generic and brand names, and purposes involved. The exact Gallup questions, if Gemini AI quoted below is correct, don't include Rx for diabetes, sleep apnea, etc. And might exclude people who take Zepbound or generic/gray/retatrutide because "such as" is a very big question.

  • Current Use: "Are you currently taking a GLP-1 prescription medication for weight loss, such as Ozempic, Wegovy, or Mounjaro?"
  • Lifetime Use: "Have you ever taken a GLP-1 prescription medication for weight loss at some point in the past?"
75% of US adults are overweight or obese, so 11% is a spit in a big bucket.
 
Honestly, in my zip code at least, there seems to be an unusually high amount of people who have not yet heard about glp1s. I talked to a woman yesterday who told me she was doing Jenny Craig and all my flabbers were gasted.
 
cldfront said:


Honestly, in my zip code at least, there seems to be an unusually high amount of people who have not yet heard about glp1s. I talked to a woman yesterday who told me she was doing Jenny Craig and all my flabbers were gasted.

Click to expand...
Click to expand...
Lol, same, one in our group is doing weight watchers meetings. Honestly did NOT know that was still a thing.
 
Back
Top